Billerud pushes fresh fiber into dry pharmaceutical packaging with PharmaKraft

The pharmaceutical packaging sector has historically been a fortress of plastics and aluminum foils, guarded by uncompromising demands for purity, barrier properties, and process reliability. Breaking into this space with fiber-based alternatives requires more than just a sustainability pitch; it demands absolute technical precision. Today, Billerud has made a significant strategic move in this direction with the global launch of PharmaKraft™, a fresh fiber material engineered specifically for non-sterile dry pharmaceutical applications.

This development represents much more than a simple catalog expansion. By targeting high-volume formats such as sachets, stick packs, strip packs, and blister lidding, Billerud is directly challenging conventional packaging structures in a segment where converting stability is non-negotiable. The Swedish manufacturer is effectively pushing paper into a highly regulated arena, aiming to prove that renewable materials can meet the stringent operational requirements of modern pharmaceutical packaging lines.

Engineering fiber for pharmaceutical demands

The core challenge in replacing fossil-based materials in pharma packaging lies in the converting process. High-speed packaging lines for stick packs and blisters tolerate zero margin for error. According to Billerud, PharmaKraft has been developed to address these exact pain points by combining reliable converting performance with controlled purity. Manufactured from fresh fiber, the material ensures the absence of contaminants that could compromise the packaged product, a critical factor for dry pharmaceuticals.

Furthermore, the material is produced with full traceability, a mandatory requirement to support the rigorous qualification and validation processes inherent to the healthcare sector. This level of documentation and quality control is what separates standard kraft papers from true medical-grade substrates.

A shifting landscape in healthcare packaging

The pressure to reduce the environmental footprint of packaging is no longer confined to fast-moving consumer goods; it has firmly reached the pharmaceutical industry. Brand owners and converters are actively seeking ways to decrease their reliance on fossil-based materials without sacrificing product safety.

Florian Schäffeler, Senior Segment Manager Medical at Billerud, highlighted this industry shift during the launch: "Healthcare packaging is entering a period of transformation. With PharmaKraft™, we have created a platform that enables innovation, supports sustainability goals, and helps accelerate the shift from conventional packaging structures to paper-based alternatives made from renewable resources."

This new product complements Billerud’s existing healthcare portfolio, which already includes established brands like SteriKraft and MediKraft for medical packaging. By adding a dedicated solution for dry pharma, the company strengthens its position as a comprehensive supplier of paper-based healthcare packaging solutions in 2026.

Market implications for converters

For converters operating in the pharmaceutical space, the introduction of PharmaKraft offers a new tool to meet the growing sustainability demands of their clients. The ability to run a recyclable, fiber-based material on existing equipment for applications like blister lidding or sachets could provide a significant competitive advantage. However, the true test will be the material's performance during the extensive validation trials required by pharmaceutical companies before any packaging change can be implemented.

Billerud's strategic push into this niche demonstrates a clear understanding of where the high-value opportunities lie in the current paper market. As standard packaging grades face intense price competition, specialized, highly technical materials like PharmaKraft offer a pathway to sustained profitability and deeper partnerships with brand owners.

The introduction of PharmaKraft is a strong signal that the technical gap between fiber and traditional pharma barriers is closing, offering converters a viable path to diversify their material mix. Will the pharmaceutical industry's strict validation processes accelerate to embrace these renewable alternatives, or will regulatory inertia slow the transition? Follow The Paper for daily news, market signals and key updates from the global paper, corrugated and packaging industry. — Sigue toda la actualidad del sector en www.thepaper.ai